Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
Eros PapademetriouXing LiuAmélie BeaudetYuen TsangRavi PotluriSumeet PanjabiPublished in: Journal of medical economics (2023)
Compared to oral and inhaled treprostinil, oral selexipag may incur lower medical costs and reduce PAH related outpatient visits for patients with PAH.